Core Viewpoint - The research team led by Liu Hui and Xu Chang has introduced a novel methodology called "evidence contamination," which aims to address biases in randomized controlled trials (RCTs) and improve the reliability of evidence in clinical guidelines [1][3][4]. Group 1: Research Findings - The team identified 1,300 problematic trials and tracked 847 evidence studies containing these trials, leading to the discovery that 20.6% of evidence conclusions changed when problematic trials were excluded [3][4]. - At least 157 international clinical guidelines were found to be influenced by these problematic conclusions, indicating a cascading effect on global medical evidence [3][4]. Group 2: Implications for Clinical Guidelines - The findings highlight significant discrepancies in clinical guidelines, such as those for the treatment of advanced liver cancer, where the National Comprehensive Cancer Network (NCCN) and the European Association for the Study of the Liver (EASL) have conflicting recommendations [3]. - The research emphasizes the need for a new approach to clinical guideline decision-making, as current practices may lead to serious medical adverse events due to unreliable evidence [3][4]. Group 3: Recognition and Future Directions - The research has been published in The BMJ, marking the first time an original theory from Chinese scholars has been featured in the journal's 180-year history, showcasing China's contributions to medical research methodology [1][5]. - The establishment of the Asia-Pacific Network for Evidence Analysis, Synthesis, and Translation (APN-EAST) aims to enhance global collaboration in evidence-based medicine and develop a system for assessing and preventing evidence contamination [5].